Friday, January 21, 2022

Advocates Focused on eliminating Type 1 Diabetes to be Honored at Boston Gala

By on May 8, 2017

SAN JUAN — Global fundraising organization JDRF’s New England Chapter has announced that Adriana Bauzá and Gerald Powderly of Newton, Mass., long-time volunteers and parents of a daughter living with type 1 diabetes (T1D), along with George L. King, chief scientific officer at Joslin Diabetes Center, and the Yale Pediatric Group, will be recognized on May 13 at “One Night,” JDRF’s 35th Annual Boston Gala, for their “steadfast commitment to curing, preventing and treating T1D.”

When Bauzá, a Puerto Rico native, and Powderly’s oldest daughter was diagnosed with type 1 diabetes in the summer of 2005 they knew they would need resources to help her any way they could. It was not surprising that once they discovered JDRF, formerly the Juvenile Diabetes Research Foundation, became fully immersed in the organization’s mission and embraced its volunteer roles, from leadership to fundraising to advocacy.

“We became involved with JDRF after our daughter’s diagnosis. After more than 10 years of living with T1D, we understand the hardships that it presents in not only Ceci’s life, but the lives of all people and families living with T1D around the world. We witness how she is constantly monitoring, balancing, correcting and adjusting her daily life. T1D is a burdensome disease with constantly overwhelming demands, causing endless stressful situations that pose real physical and mental health risks. As a formidable foe, it would be easy to let T1D win, but we are the type to fight!” the couple said in a release announcing the recognition.

Powderly served on the organization’s New England Chapter board for six years, two of which as president. As a JDRF ambassador, he established connections between his chapter and local corporations including his own employer, Deloitte. Bauzá is actively engaged with JDRF’s gala and outreach committees. She regularly organizes outreach caregiver events and can always be counted on to passionately support newly diagnosed families through “Bag of Hope” deliveries.

The couple’s entire family, both stateside and in Puerto Rico, has been long-time philanthropic supporters of JDRF, participating in the endurance programs, peer-to-peer programs as well as the JDRF Boston Gala. “Their impact and legacy is remarkable and JDRF is indebted to the family for their steadfast support and leadership,” the organization says in the release.

“Ceci’s diagnosis has sent us on a life mission; the mission to one day cure T1D. As a family, we are committed to supporting JDRF, the largest private funder of T1D research in the world. Dealing with this taxing condition alone would be close to impossible. In addition to supporting the most promising T1D research, JDRF provides a strong support network to our family and we are honored to give back to the JDRF community. Our dedication to JDRF is simply part of who we are, which is why we are deeply humbled to be honored at this year’s One Night―35th Annual JDRF Boston Gala.”



“Nani and Gerry truly embody all that makes JDRF special and successful. We are delighted to honor their unwavering dedication to bringing support, better treatments and ultimately a cure for all those living with type 1 diabetes around the world,” Amy Montalto, executive director of JDRF New England, added.

This year’s gala aims to raise more than $2 million through silent, live and “Fund A Cure” auctions for T1D research. The organization says it has invested nearly $2 billion since its inception on its mission “to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications.”

The organization has accomplished this using a grassroots model of people connecting in their local communities, collaborating regionally and broader fundraising, and “uniting on a national stage to pool resources, passion, and energy.” Its staff and volunteers in more than 100 locations throughout the United States and six international affiliates collaborate with academic institutions, policymakers, and corporate and industry partners “to develop and deliver a pipeline of innovative therapies to people living with T1D.”

For more information or to support the event, visit:

You must be logged in to post a comment Login